Starting long acting bronchodilators for COPD is associated with increased cardiovascular risk, finds studyBMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k11 (Published 03 January 2018) Cite this as: BMJ 2018;360:k11
- Susan Mayor
Initiating treatment of chronic obstructive pulmonary disease (COPD) with a long acting β2 agonist or a long acting antimuscarinic antagonist is associated with a 50% higher risk of serious cardiovascular events, including in patients with no previous cardiovascular disease, a large case-control study has found.1
Inhaled long acting bronchodilators are the standard treatment for COPD, and data on cardiovascular risk has been mixed.
Researchers used data from the Taiwan National Health Insurance …